Rusfertide Reduces Phlebotomy Need, Improves Quality of Life in Polycythemia Vera
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
Read More
Oncology Nurse Amanda Snyder Turns Personal Experience Into Advocacy
Amanda Snyder, a cancer survivor, became an oncology nurse to provide support she once lacked, now leading innovative therapies for patients.
Understanding Breast Cancer Biomarkers Drives Patient Treatment Decisions
Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2-negative disease.
Zilovertamab Vedotin Plus Chemo Combo Shows Responses in R/R DLBCL
The antibody-drug conjugate zilovertamab vedotin plus Rituxan and chemotherapy showed an objective response rate of 56.3% in relapsed/refractory DLBCL.
Targeted Chemo Improves Survival in Early-Stage Lung Cancer
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
Utilizing AI in Prostate Cancer Care and Management
How artificial intelligence is being used to augment the work of experts treating patients with prostate cancer.
KITE-363 Shows High Response in B-Cell Lymphoma With Manageable Safety
The dual-targeting CAR T-cell therapy KITE-363 showed positive response rates and manageable side effects in relapsed or refractory B-cell lymphoma.
Zyprexa Added to Standard Antiemetics Reduces Nausea, Vomiting in Radiation
Adding Zyprexa to ondansetron cut nausea and vomiting safely in abdominal/pelvic radiation with low-emetogenic capecitabine.
Sasanlimab-BCG Combo May Delay Recurrence in Bladder Cancer
Adding subcutaneous sasanlimab to BCG improved recurrence-free survival in non–muscle-invasive bladder cancer, according to Dr. Petros Grivas.
Watch
A Unicorn Among Us
Katherine has an exquisite instinct for understanding that there is a context to each patient’s diagnosis that is just as important to understand.
Columvi Combo Enhances Survival Outcomes in R/R Lymphoma Subgroup
Columvi plus chemo had enhanced survival outcomes vs Rituxan plus chemo in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nubeqa Combo Positively Impacts HRQoL vs Placebo in Prostate Cancer Subgroup
Nubeqa and ADT treatment led to positive impacts on health-related quality of life vs placebo in metastatic hormone-sensitive prostate cancer.
Imdelltra Shows Survival Benefit in Small Cell Lung Cancer
Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, reinforcing it as a new SOC.
Targeting ESR1 Mutations Early May Improve Outcomes in Breast Cancer
Dr. Massimo Cristofanilli discusses the early use of camizestrant with a CDK4/6 inhibitor to target ESR1 mutations, as it may improve outcomes in metastatic breast cancer.
Patritumab Deruxtecan Does Not Improve Survival Outcomes vs Chemo in EGFR+ NSCLC
Patritumab deruxtecan treatment did not improve suvival end points versus those treated with chemotherapy in EGFR+ advanced/metastatic NSCLC.
Kisqali Benefit Lasts Across Age in Breast Cancer Subset
Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.
COCOON Regimen Eases Dermatologic Side Effects After Treatment in EGFR+ NSCLC
The COCOON dermatologic management regimen reduced the quality-of-life impact of Rybrevant/Lazcluze vs SOC treatment in patients with EGFR-mutated NSCLC.
Akeega Combo Delays Progression in HRR+ Castration-Sensitive Prostate Cancer
Akeega delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer and HRR gene mutations.
Understanding the Side Effects of RLY-2608 in HR+, HER2– Breast Cancer
Dr. Sarah Sammons discusses side effects associated with RLY-2608, and how it effects patients with HR-positive, HER2-negative advanced breast cancer.
Imlunestrant Alone or With Verzenios Improved PROs in Advanced Breast Cancer
Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy.
Initial Enhertu Combo Improves Survival in HER2+ Advanced Breast Cancer
Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09.
Exercise Improves Survival End Points After High-Risk CRC Treatment
Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC.
Breaking Down the CheckMate 901 Trial Data for Metastatic Bladder Cancer
Dr. Guru Sonpavde discusses the CheckMate 901 trial evaluating Opdivo plus Yervoy for those with cisplatin-ineligible, metastatic urothelial carcinoma.
Imfinzi Combo Boosts Survival in Resectable Gastric and GEJ Cancer
Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer.
Tecentriq Plus Chemo Reduced Risk of Death vs Chemo Alone in dMMR Colon Cancer
Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, stage 3 colorectal cancer.
Camizestrant and CDK4/6 Inhibition Benefits Outcomes in Breast Cancer Subgroups
Camizestrant and continued therapy with CDK4/6 inhibition benefits patients who present with ESR1-mutated, ER+, HER2– advanced breast cancer.
Adjuvant Opdivo Combo Improves Survival Outcomes in Advanced Head and Neck Cancer
Adjuvant Opdivo, cisplatin and radiotherapy improved DFS vs other treatment among those with locally advanced squamous cell carcinoma of the head and neck.
Trodelvy/Keytruda Extends PFS Versus Chemo/Keytruda in PD -L1+ TNBC
Trodelvy plus Keytruda, when given in the frontline, extended survival without progression versus chemo plus Keytruda in PD-L1+ metastatic TNBC.
Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ
Second-line Enhertu improved key survival end points versus Cyramza plus paclitaxel for HER2+ gastric cancer or gastroesophageal junction adenocarcinoma.
Vepdegestrant Boosts Outcomes in ESR1-Mutant ER+/HER2– Advanced Breast Cancer
Among patients with ESR1-mutant, ER+, HER2– advanced breast cancer, vepdegestrant improved survival without progression when compared with Faslodex.